SCHEMBL5366800

SCHEMBL5366800

O=C1Nc2ccc(I)cc2C1=Cc1ccc(Br)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.70
RAF1 P04049 3/20 0.70
MAP1LC3B Q9GZQ8 3/20 0.70
PLK4 O00444 3/20 0.70
APP P05067 2/20 0.70
MEN1 O00255 2/20 0.70
KMT2A Q03164 2/20 0.70
EGFR P00533 1/20 0.70
NTRK1 P04629 1/20 0.70
ARAF P10398 1/20 0.70
PIM1 P11309 1/20 0.70
BRAF P15056 1/20 0.70
CSNK2A1 P68400 1/20 0.70
PIM3 Q86V86 1/20 0.70
SIRT2 Q8IXJ6 1/20 0.70
SIRT1 Q96EB6 1/20 0.70
MYOC Q99972 1/20 0.70
DYRK4 Q9NR20 1/20 0.70
SIRT3 Q9NTG7 1/20 0.70
SIRT5 Q9NXA8 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5370064 0.86 PSEN1 (0.71) MAPTRAF1MAP1LC3BPLK4APP
SCHEMBL5373326 0.86 MAPT (0.70) MAPTRAF1MAP1LC3BPLK4APP
SCHEMBL7138082 0.86 MAPT (0.70) MAPTRAF1MAP1LC3BPLK4APP
SCHEMBL7132904 0.86 MAPT (0.74) MAPTRAF1MAP1LC3BPLK4APP
SCHEMBL5358659 0.85 LRRK2 (0.69) MAPTRAF1MAP1LC3BPLK4APP
SCHEMBL5358886 0.85 PLK4 (0.65) MAPTRAF1MAP1LC3BPLK4APP
SCHEMBL7133779 0.83 MAPT (0.67) MAPTRAF1MAP1LC3BPLK4APP
SCHEMBL7985978 0.83 RAF1 (0.70) MAPTRAF1MAP1LC3BPLK4APP
SCHEMBL5361840 0.83 MAPT (0.66) MAPTRAF1MAP1LC3BPLK4APP
SCHEMBL5480439 0.83 LRRK2 (0.75) PLK4MEN1KMT2ALRRK2PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MAPT 3048/4885RAF1 245/4885MAP1LC3B 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.